Webinar on de-escalation of breast cancer treatments organised by EORTC and BIG

The month of October is international breast cancer awareness month. In this context, yesterday Wednesday 14 October, the European Organisation for Research and Treatment of Cancer (EORTC) and the Breast International Group (BIG against breast cancer) organised a webinar on breast cancer addressed to the general public.

The purpose of the webinar, which counted 169 participants from different countries, was to raise awareness about breast cancer and the importance of international academic research.

The main topic of the session focussed on the growing importance of treatment de-escalation to improve breast cancer patients’ quality of life by avoiding unnecessary over-treatment. Breast cancer experts from the EORTC and BIG networks gave examples of de-escalation clinical trials and explained how they may help breast cancer patients by safely reducing treatment burden. A patient advocate from Europa Donna also gave her perspective on this topic.

If you missed the webinar, you can view the recording here.

The session included the following presentations:

  • Brief introduction on global breast cancer research and de-escalation of breast cancer treatments – By Prof. Etienne Brain, EORTC Breast Cancer Group Chair & BIG Executive Board member (Brussels, Belgium)
  • Brief presentation of DESCRESCENDO study and introduction of the speakers – By Prof. David Cameron, BIG Chair and EORTC Breast Cancer Group member (Edinburgh, UK)
  • Tailoring radio therapy after surgery to an individual patient’s risk of recurrence (EXPERT study – BIG Radio Tuning). Tailoring radiation dose escalation after surgery: cosmetic results and patient reported outcomes informing treatment decision-making (DCIS study) – By Prof. Boon Chua, BIG Executive Board member & Study Principal Investigator of EXPERT and DCIS (Sydney, Australia)
  • Using the biological characteristics of a tumour and novel diagnostic tests to help safely exclude chemotherapy (MINDACT study) – By Prof. Fatima Cardoso, EORTC Breast Cancer Group and BIG member & Study Principal Investigator of MINDACT
  • Getting the patient’s perspective: Importance of giving patients the right information about de-escalation risks – By Mrs Elizabeth Bergsten Nordstrom, EUROPA DONNA Executive Board member

During the session, participants – who were a mix of breast cancer patients, advocates, family members, students, researchers and breast cancer specialists – were also invited to ask the speakers any questions they had, allowing for a true learning and sharing experience.

EORTC and BIG teams would like to thank the speakers and all participants for this interesting session!

Back to news list

Related News

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC